InvestorsHub Logo
Followers 33
Posts 2854
Boards Moderated 1
Alias Born 10/24/2015

Re: None

Thursday, 10/15/2020 9:25:55 PM

Thursday, October 15, 2020 9:25:55 PM

Post# of 154
A CAR-NK cell product targeting MICA/B should overcome solid tumor escape from NKG2D-mediated mechanisms of recognition and killing.

A paper demonstrated that antibody targeting of the MICA/B a3 domains specifically prevents shedding and is able to restore NK cell-mediated immunity [1]. Additionally, cancers with B2M and JAK1 inactivating mutations which result in the loss of MHC Class I expression can be effectively targeted with a MICA/B a3 domain-specific antibody to restore NK cell-mediated immunity against solid tumours resistant to cytotoxic T-cells [2].

Refs:
1 https://science.sciencemag.org/content/359/6383/1537.full
2 https://cancerimmunolres.aacrjournals.org/content/8/6/769.long
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NKTX News